Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Neoplasms 2Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms by Site 1Neoplasm, Residual 1Lung Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Bronchogenic 1

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Tyrosine Kinase Inhibitors × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡